BIBLIOGRAFÍA 1.- Bailey AJ,Sims TJ, Avery NC et al. Chemistry of Collagen crosslinks; glucose-mediated covalent cross-linking of type-IV collagen in lens capsules. Biochem J 296:489-96, 1993. 2.- Brett J, Schmidt AM, Yan SD, et al. Surgery of the distribution of the distribution of a newly characterized receptor for advanced glycation endproducts in tissues. Am J Pathol, 143:1699-17712, 1993. 3.- Brownlee M, ViassaraH, Kenney A, et al. Aminoguanidine prevents diabetes-induced arterial wall protein crosslinking. Science 232:1629-32,1986. 4 - Bucla R, Makita Z, Veta G, et al. Modification of LDL by advanced glucosylation endproduct contribues to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 91:9441-5, 1994 5.- Bucla R, Makita Z, Veta G, et al. Modification of LDL by advanced glucosylation endproduct contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 91:9441-5, 1994 6.- Bucala R, Tracey KJ, Cerami A. Advanced Glycosylation products quench nitric oxide mediate defective endothelium-dependent vasodilatation in exporimental diabetes. J Clin Invest 87:432-8, 1991. 7.-Bucala R, Viassara H, Cerami A. Advanced Glycoylation endproducts. In: JJ Harding, MJC Cribbeeds. Post translational modification of proteins. Boca Raton, FL, CRC Press Inc, 2:53-79, 1992. 8.- Cameron NE, Cotter MA, Dines K, et al. Effects of aminoguanidine on poripheral nerve faction and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetología 35:946-50, 1992. 9.-Cho HK, Peyman GA, et al. The effect of aminoguanidine on the bloodretinal barrier in streptozotocin-induced diabetic rats. Ophtalmic 22:44-7, 1991. 10.- De Tejada IS, Gldstein I, Adzazoi K, et al. Imparied neurogenic and endothelium-mediated relaxation of penile smooth muscle in diabetic men with impotence. N Engl J Med 320:1025-30, 1989 11.- Doi T, Vlassara H, Kirstein M, et al Receptor-specific increased mesangial cell extracellular matrix production is mediated by PDGF. Proc Natl Acad Sci USA, 89:2873-9, 1992. 12.- Dyer DG, Blackledge JA, Thorpe SR, et al. The Maillard reaction in vivo. Zeitschrift fur Emahrrmgwissenschaft, 30:29-45, 1991. 13.- Dyer DG, Blackledge JA, Katz BM, et al. Formation of pentosidine dining nonenzymatic browning of proteins by glucose: Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 266:11654-60,1991. 14.- Edelstein D, Vrroenlee M. Aminoguanidine ameliorates albuminuria in diabetic hyportensive rats. Diabetologia 35:95-7, 1992. 15.- Ellis EN, Good BH, Prevention of glomerdar basement membrane thickening by aminoguanidine in exporimental diabetes mellitus. Metabolism 40:1016-9, 1991. 16.- Esposito C, Stern D, Gerlach H, et al. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer pormeability and modulation of cell surface coagulant proporties. J Exp Med 170:1387-1407, 1989. 17.-FuMX, Well-Knecht KJ, Blackledge JA, et al. Glycation, glycoxidation and cross-linking of collagen by glucose: Kinetics, mechanisms and inhibition of late stages of the Maillard reaction. Diabetes 43:676-83, 1994. 18.- Gascho JA, Fanelli C, Zelis R. Aging reduces venous distensibility and the venodilatory response to nitroglucerin in normal subjects. Am J Cardiol 63:1267-70.1, 1989. 19.- Hammes HP, Brownlee M, Edelsten D, et al. Aminoguanidine inhibits the development of exporimental diabetic retinopathy in the SHR. Diabetologia 37:32-5, 1994. 20.- Hammes HP, Martin S, Federlin K, et al. Amiguanidine treatment inhibits the development of exporimental diabetic retinopathy. Proc Natl Acad Sci USA 88:11555-8, 1991. 21.- Hogan M, Ceami A, Bucala R. Advances glycosylation end products block the antiproliferative effect of nitric oxide. J Clin Invest 90:110-5, 1992. 22.- Horiuchi S, Araki N, Morina Y. Inmunochemical approach to characterize advanced glycation endproducts of the Maillard reaction. J Biol Chem 266:7329-32, 1991. 23.- Huibert MSP, Wolfenbuttel BHR, Crrs FR, et al. Aminoguanidine reduces regional albumin clearance but not urinary albumin excretion in streptoxotocin-diabetic rats. Diabetologia 37:10-4, 1994. 24.- Huibert MSP, Wolfenbuttel BHR,Strujker-BOndler HAJ, et al. Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J Clin Invest 92:1407-11, 1993. 25.- Imani F, HomY Suthanthran M, et al. Advances glycosylation endproduct-specific receptors on human and rat T-limphocytes mediate synthesis of interferon-y. Role in tissue remodeling. J Exp Med 178:2165-72, 1993. 26.- Imani F, WojciechowiczM, Skolnik EY et al. Serum Mac-2 or carbohydrate binding protein-35 (CBP) binds glycated proteins and is elevated in diabetic sera. Faseb Journal 8:A1385, 1994. 27.- Itakura M, Yoshikawa H, Bannai C, et al. Aminoguanidine decreases urinary albumin and high-molecular-weight proteins in diabetic rats. Life Sci, 49:889-897, 1991. 28.- Kijara J, Schrneizer JD, Podusio JF, et al. Aminoguanidine effects on nerve blood flow, vascular pormeability, elecrophysilogy and oxygen free radicals. Proc Natl Acad USA 88:6107-11, 1991. 29.- Kirstein M, Brett J, Radoff S, et al. Advanced glycosylation endproducts selectively induce monocyte migration across in the endothelial cell monolayers and elaboration of growht factors: role in aging and diabetic vasculopathy. Proc Natl Acad Sci USA 87:9010-4, 1990. 30.- Libby P, Hansson GK. Involument of the immune system in human atherogenesis: current knowledge and unanswered questions. 31.- Makita Z, Bukala R, payfield EJ, et al. Reactive glycosylation enproducts in diabetic uremia and treatment of renal failure, Lancet 343:151922, 1994. 32.- Makita Z, Radolf S, Rayfield EJ, et al. Avanced glycosylation endproducts in patients with diabetic nephopathy. N Engl J Med 325:836-842, 1991. 33.- Makita Z, Vlassara H, Cirami A, et al. Inmunochemical detection of advanced glycosylation endproducts in vivo. J Biol Chem 267:5133-8, 1992. 34.-Makita Z, Vlasara H, Rayfield E.I, et al. Hemoglobin AGE: a circulating marker of advanced glycosylation. Science 258:651-3, 1992. 35.- McVeigh GE, Brennan GM, Johnston GD, et al. Impaired endothelialdependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetología 35:771-6, 1992. 36.- Miyata T, Inagi R, Ida Y, et al. B2-microglobulin modified with advanced glycation endproducts in the pathogenesis of hemodialysis-associated amyloidosis. J Clin Invest 93:521-6, 1994. 37.- Miyata T, Oda O, Inagi R, et al. B2-microglobulin modified with advanced glycation eproducts is a major component of Iremodialysis-associated amyloidosis. J Clin Invest 92:1243-52, 1993. 38.- Nakamura K Hasegawa T, Furunaga Y, et al. Crosslines A and B as candidates for the fluorophores in age-and diabetes-related cross-linked proteins and their diacetates produced by Maillard reaction of a-N-Acetyl-L-lysine with D-glucose. J Client Soc Chem Coirumm 992-4, 1992. 39.- Nakayama H, Taneda S, Fukunaga Y et al. Production and chareacterization of antibodies to advanced glycation products on proteins. Biochem Biophys Res Comm, 162:740-5, 1989. 40.- Neepor M, Schmidt AM, Brett .l, et al. Cloning and expression of a cell surface receptor for advanced glycation end products of proteins. J Biol Chem, 267:14998-15004, 1992. 41 .- Nicholls K, Manuel TE. Advanced glycosylation endproducts in exporimental marine diabetic nephropathy. Effect or islet isografting and of aminoguanidine. J Lab Invest 60:486-91, 1989. 42.- Odetti PR, Borgoglio A, De Pascale A, et al. Prevention of diabetes increased aging effect on rat collagen-linked fluorescence by aminoguanidine and Faun. Diabetes 39:796-800, 1990. 43.- Oxlund H, Andreassen TT. Aminoguanidine treatment reduces the increases in collagen stability of rats with exporimental diabetes mellitus Diabetologia 35:75-8, 1992. 44.-Schmidt AM, Vianna M, Gerlach M, et al. Isolation and characterization of two binding proteins for advanced glycosylation end products horn bovine lung which are present on the endothelial cell surface. J Biol Chem 256:1498797, 1997. 45.- Skolnik EY, Yang Z, Makita Z, et al. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephopathy. J Exp Med 174:931-9, 1996. 46.- Soulis-Laparota T, Coopor M, Papazoglu, et al. Retardation by aminoguanidine of development of albumimrria, mesangial expansion and tissue fluorescence in streptozotocin-induced diabetic rat. Diabetes 40:1328-34, 1991 47.- The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longtern complications in insulin-dependent diabetes mellitus. N Engl J Med, 329:977-86, 1998. 48.- United Statews Renal Data System, USRDS 1997 Annual Data Report The Nacional Institute of Diabetes and Digestive and Kidney Disease. Behsda Maryland, August 1997. 49.- Vlassara H. Non-enzymatic glycosylation. Diabetes, Annual/6 18:37189, 1996. 50.- Vlassara H, Bucala R, Striker L Pathogenic effects of advanced glycosylation: biochemical and aging. J Lab Invest 70:138-51, 1994. 51.- Vlassara H, Brownlee M, Cerami A. High.affinity receptor-mediated uptake and degradation of glucose-modified proteins: A potential mechanism for the removal of senescent macromolecules Proc Nail Acad Set USA 82:558892,1995. 52.- Vlassara H, Browlee M, Cerami A. Novel macophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors. J Exp Med 164:1300-9, 1992 53.- Vlassara H, Brownle M, Manogee KR, et al. Cacheti/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodelling. Science 240:1546-8, 1993. 54.- Vlassara H, Fuli H, Makita Z, et al. Exogenous advanced glycosylation endproducts induce complexe vascular dysfunction in normal animals. A model for diabetic and aging complications. Proc Nail Acad Sci USA, 89:12043-7, 1997. 55.- Vlassara H, Striker LJ, Teichberg S, et al. Advanced glycosylation endproducts induce glomerular sclerosis and albumimuia in normal rats. Proc Natl Acad Sci USA 91:11704-8, 1994. 56.- Yagihashi S, Kamijo M, Baba M, et al. Effect of aminoguanidine on functional and structural abnormalities in poripheral nerves of STZ-induced diabetic rats. Diabetes 41:47-52, 1997. 57.- Yang GW, Vlassara H, Peten EP, et al. Advanced glycosylation endproducts upregulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sc) USA 91:9436-40, 1996. 58.- Yang GW, Makita Z, Horii Y, et al. Two novel rat liver membrane proteins that bind avanced glycosylation endproducts : relationship to macropliage receptor for glucose-modified proteins J Exp Med. 174:515-24, 1996.
|
